2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor

Insulin Receptor

Insulin Receptor

Related Products

PDF 0.56 MB

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10252A
    cis-NVP-ADW742
    cis-NVP-ADW742 (cis-ADW742) is a cis isomer of NVP-ADW742 (HY-10252). NVP-ADW742 is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.
    cis-NVP-ADW742
  • HY-P1773
    IGF-I (30-41)
    IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
    IGF-I (30-41)
  • HY-W207669
    Centpiperalone
    		Activator
    Centpiperalone is an orally active hypoglycemic agent. Centpiperalone mainly achieves its hypoglycemic effect by promoting the release of insulin by pancreatic β cells. Centpiperalone can effectively lower blood sugar levels in both normal and diabetic animals. Centpiperalone can be used in research on diabetes.
    Centpiperalone
  • HY-P992087
    Insulin eflivet
    		Inhibitor
    Insulin eflivet is a recombinant antibody targeting insulin receptor. Insulin eflivet can be used in diabetes research.
    Insulin eflivet
  • HY-103545
    GIP (1-39)
    		Agonist
    GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca2+ concentration ([Ca2+]i), and capable of enhancing exocytosis.
    GIP (1-39)
  • HY-138842
    DDN
    		Activator
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice.
    DDN
  • HY-19960R
    BCTC (Standard)
    		Agonist
    BCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
    BCTC (Standard)
  • HY-10200R
    BMS-754807 (Standard)
    		Inhibitor
    BMS-754807 (Standard) is the analytical standard of BMS-754807 (HY-10200). This product is intended for research and analytical applications. BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively.
    BMS-754807 (Standard)
  • HY-13203R
    NVP-TAE 226 (Standard)
    		Inhibitor
    NVP-TAE 226 (Standard) is the analytical standard of NVP-TAE 226. This product is intended for research and analytical applications. NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively.
    NVP-TAE 226 (Standard)
  • HY-15656R
    Ceritinib (Standard)
    		Inhibitor
    Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
    Ceritinib (Standard)
  • HY-10191R
    Linsitinib (Standard)
    		Inhibitor
    Linsitinib (Standard) is the analytical standard of Linsitinib. This product is intended for research and analytical applications. Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
    Linsitinib (Standard)
  • HY-108719R
    Insulin glargine (Standard)
    Insulin glargine (Standard) is the analytical standard of Insulin glargine (HY-108719). This product is intended for research and analytical applications. Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells.
    Insulin glargine (Standard)
  • HY-W010271R
    (2S,3R,4S)-4-Hydroxyisoleucine (Standard)
    (2S,3R,4S)-4-Hydroxyisoleucine (Standard) is the analytical standard of (2S,3R,4S)-4-Hydroxyisoleucine (HY-W010271). This product is intended for research and analytical applications. (2S,3R,4S)-4-Hydroxyisoleucine is an orally active compound. (2S,3R,4S)-4-Hydroxyisoleucine can be isolated from Trigonella foenum-graecum. (2S,3R,4S)-4-Hydroxyisoleucine has anti-diabetic and anti-diabetic nephropathy activity.
    (2S,3R,4S)-4-Hydroxyisoleucine (Standard)
  • HY-163652
    Glicetanile
    Glicetanile is an orally active hypoglycemic agent, that stimulates the release of insulin from pancreatic beta cells, and lowers the blood sugar. Glicetanile exhibits potential in ameliorating the type 2 diabetes.
    Glicetanile
  • HY-P990867
    Anti-CD220/Insulin Receptor Antibody (IR 83-22)
    		Inhibitor
    Anti-CD220/Insulin Receptor Antibody (IR 83-22) is an anti-human CD220/Insulin Receptor IgG1 monoclonal antibody. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can block Akt overactivation caused by Trip13 deficiency. Anti-CD220/Insulin Receptor Antibody (IR 83-22) can be used for research on cancer such as hepatocellular carcinoma (HCC). Anti-CD220/Insulin Receptor Antibody (IR 83-22) often used in western blotting. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-CD220/Insulin Receptor Antibody (IR 83-22)
  • HY-183840
    PP185
    		Substrate
    PP185 is a insulin receptor kinase substrate. PP185 undergoes rapid tyrosine phosphorylation, with activity dependent on divalent cations and inhibited by insulin receptor kinase domain antibodies. PP185 can be used for the research of neuroblastoma.
    PP185
  • HY-100037R
    NT157 (Standard)
    		Inhibitor
    NT157 (Standard) is the analytical standard of NT157 (HY-100037). This product is intended for research and analytical applications. NT157 (Tyrphostin NT157) is a selective IRS-1/2 inhibitor that induces Ser-phosphorylation and consequently the degradation of IRS-1/2. NT157 (Tyrphostin NT157) is a first-in-class anti-cancer agent that also targets Stat3 signaling pathway.
    NT157 (Standard)
  • HY-14243
    CEP-14083
    		Inhibitor
    CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma.
    CEP-14083
  • HY-W516943
    CI-624
    		Inhibitor
    CI-624 decrease secretion volumes and outputs of hydrogen, sodium and potassium ions and of pepsin. CI-624 can be used in the research of cancer and autoimmune diseases.
    CI-624
  • HY-10524R
    GSK1904529A (Standard)
    		Inhibitor
    GSK1904529A (Standard) is the analytical standard of GSK1904529A (HY-10524). This product is intended for research and analytical applications. GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity.
    GSK1904529A (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity